Evidence map›Paper›PMID 26834486›Full record

ArticleOncoTargets and therapy2016

Polymorphisms in RAD51 and their relation with breast cancer in Saudi females.

Sahar Tulbah, Huda Alabdulkarim, Mohammad Alanazi, Narasimha Reddy Parine, Jilani Shaik, Akbar Ali Khan Pathan, Abdullah Al-Amri, Wajahatullah Khan, Arjumand Warsy

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Genetic Variants inGenes · 2025
    Article
  5. Article
  6. Cancers · 2022
    Article
  7. Article
  8. Article
  9. Modification ofInternational journal of environmental research and public health · 2020
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Sahar TulbahDepartment of Biochemistry, College of Science, King Saud University, Center of Scientific and Medical Colleges, Riyadh, Saudi Arabia.
Huda AlabdulkarimDepartment of Hematology/Oncology, King Fahad Medical City Hospital, Comprehensive Cancer Center, King Saud University, Riyadh, Saudi Arabia.
Mohammad AlanaziDepartment of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Narasimha Reddy ParineDepartment of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Jilani ShaikDepartment of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Akbar Ali Khan PathanDepartment of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Abdullah Al-AmriDepartment of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
Wajahatullah KhanBasic Sciences Department, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Arjumand WarsyDepartment of Biochemistry, College of Science, King Saud University, Center of Scientific and Medical Colleges, Riyadh, Saudi Arabia.
King Saud University · SAThe King's College · USKing Fahd Medical City · SAKing Saud bin Abdulaziz University for Health Sciences · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed at investigating the relationship between rs1801320 (G>C), rs1801321 (G>T), and rs2619681 (C>T) RAD51 gene polymorphisms and the risk of breast cancer development in Saudi females. The genotypes were analyzed using TaqMan genotyping assay and polymerase chain reaction-restriction fragment length polymorphism. The genotype and allele frequencies were computed using chi-square or Fisher's exact test (two-tailed) by SPSS 21 software. The results showed that rs1801321G>T GG genotype and G allele frequency were strongly (P<0.0001) related to an elevated risk of breast cancer, while the mutant T allele appeared to provide protection against breast cancer development as observed from the significantly lower (P<0.0001) frequencies of the TT and GT genotypes in cancer patients compared to the healthy controls. The variant rs1801320G>C showed no significant differences in the frequencies of the genotypes and alleles in the patients and the control groups. The CC genotype and C allele frequency of rs2619681 (C>T) variant were significantly (P=0.012) higher in cancer patients, whereas the T allele showed a protective effect against cancer development. The frequencies of the three single-nucleotide polymorphisms did not differ in cancer patients with different tumor grades and human epidermal growth factor receptor 2 status (+ or -). However, the genotype frequency of rs1801320 (135G>C) differed in the patients with estrogen receptor (ER)+ and ER-, where CC genotype showed a significantly higher prevalence in the females with ER- who were suffering from breast cancer. In addition, the frequency of C allele of rs2619681 (C>T) was also significantly higher in the breast cancer patients who were ER+ and progesterone receptor (PR)+ compared to those with ER- and PR-. In the Saudi females, rs1801320 did not show an association with risk of breast cancer. Taken together, the results suggest that RAD51 rs1801321 polymorphism may be involved in the etiology of breast cancer in the Saudi females; however, further studies are necessary to confirm this relation.

Indexed as

breast cancerRAD51Saudi Arabiasingle nucleotide polymorphism

Identifiers

PMID26834486
PMCPMC4716748
OpenAlexW2236472034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.